MedTrace Logo

SA4503 8-Week Study in Major Depressive Disorder (MDD)

NCT00551109 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-12-18

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of SA4503 compared to placebo in the treatment of subjects with major depressive disorder (MDD). Secondary, to evaluate the safety of SA4503 compared to placebo in subjects with MDD.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

placebo

placebo, oral administration, once daily for 8 weeks

DRUG

SA4503 Low

Low dose, oral administration, once daily for 8 weeks

DRUG

SA4503 High

High dose, oral administration, once daily for 8 weeks

Sponsors & Collaborators

  • M's Science Corporation

    lead INDUSTRY

Principal Investigators

  • Björn Appelberg, MD, PhD · Helsinki University Central Hospital, Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Completion
2008-09-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00551109 on ClinicalTrials.gov